Literature DB >> 23064078

[Reduction of angialgia during peripheral administration of oxaliplatin mixed with dexamethasone].

Yuki Shiotsuka1, Miki Uebuchi, Seiji Hamada, Naofumi Morita, Akira Moriyama, Mayuko Yamashita, Yasuko Ichikawa, Hiroshi Fujii, Akinobu Matsuo, Hiroshi Kuhara, Yoshiaki Ikuta, Satoshi Ikeshima, Masafumi Kuramoto, Kenichiro Fujii, Shinya Shimada.   

Abstract

Seven patients who had been receiving capecitabine+oxaliplatin±bevacizumab(CapeOX±BV)therapy at our hospital between February 2010 and March 2011, had complained of angialgia during oxaliplatin(L-OHP)administration. Therefore, 3. 3 mg of dexamethasone(DEX)was added to their infusion solution. The patients were then asked to rate their angialgia severity using a numerical rating scale(NRS), when L-OHP in a 5% dextrose solution was administered with or without DEX. By changing the L-OHP in 5% dextrose solution without DEX to the solution containing 3. 3 mg of DEX, the mean NRS was improved to 2. 4 from 7. 1. These findings indicate that L-OHP in 5% dextrose solution mixed with 3. 3 mg of DEX seems to be useful in reducing angialgia during peripheral administration of L-OHP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23064078

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods.

Authors:  Yukio Suga; Nana Ikeda; Manami Maeda; Angelina Yukiko Staub; Tsutomu Shimada; Miwa Yonezawa; Hironori Kitade; Hideyuki Katsura; Morihiro Okada; Junko Ishizaki; Yoshimichi Sai; Ryo Matsushita
Journal:  J Pharm Health Care Sci       Date:  2018-08-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.